PRESS RELEASE published on 06/07/2024 at 17:45, 5 months 13 days ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and share capital as of May 31, 2024, in compliance with French regulations. The company specializes in AI-driven solutions for cancer diagnosis and treatment Share Capital Voting Rights AI Solutions Median Technologies Cancer Diagnosis
BRIEF published on 05/29/2024 at 17:50, 5 months 22 days ago Median Technologies to Attend 2024 ASCO Annual Meeting in Chicago Clinical Trials Oncology Imaging Solutions Median Technologies ASCO Annual Meeting
PRESS RELEASE published on 05/29/2024 at 17:45, 5 months 22 days ago Inside Information / Other news releases Median Technologies to participate in the 2024 ASCO Annual Meeting at McCormick Place, Chicago, IL, USA. Abstract on double reading performance in lung clinical trials. Event details and company overview Clinical Trials Oncology Medical Imaging Median Technologies ASCO Annual Meeting
BRIEF published on 05/21/2024 at 17:50, 5 months 30 days ago Median Technologies strengthens its position with pharmaceutical giants Artificial Intelligence Oncology Medical Imaging Median Technologies Clinical Tests
BRIEF published on 05/10/2024 at 17:50, 6 months 10 days ago Median Technologies Announces Update on Shares Voting Rights Voting Rights Median Technologies Share Structure French Corporate Law Non-voting Shares
PRESS RELEASE published on 05/10/2024 at 17:45, 6 months 10 days ago Changes in the rights attaching to the classes of shares or securities Press release about disclosing the total number of voting rights and shares in Median Technologies as of April 30th, 2024 Voting Rights Shares Median Technologies Innovative Imaging Solutions French SME Equity
Published on 11/21/2024 at 13:30, 29 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 29 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 59 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 59 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 59 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 24 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 44 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 1 minute ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 39 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
